The National Health Commission (NHC) of China has released its third list of drugs recommended for generic development, comprising 39 varieties with 75 specifications and 13 dosage forms. These cover a broad range of therapies including anti-tumor drugs, immunomodulators, anti-infective drugs, nervous system drugs, radiation diagnostic agents, and cardiovascular system drugs, spanning 12 treatment areas. The updated list no longer includes lefamulin and Ga-68 PSMA-11, which were present in the October 2023 list.
The first two lists, totaling 33 varieties, have seen marketing approvals for drugs in 15 treatment areas, including anti-infective, anti-tumor, and immune modulators, with 7 of these targeting rare diseases. Of these, 14 were approved with priority review status, and 12 have been included in the National Reimbursement Drug List (NRDL) through negotiations. These approvals have facilitated:
- Ordered guidance for enterprise R&D to ensure medication accessibility.
- Sufficient market competition to guarantee drug supply.
- Integration with drug regulatory policies to expedite the launch of urgently needed drugs.
- Connection with medical insurance policies to enhance medication accessibility.- Flcube.com
